反应详情

A solution of N-[(5S)-3-carboxy-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide (0.3 g; 0.779 mmol), (Med. Chem. Res. 1991, 142), DCCI (0.322 g; 1.55 mmol), DMAP (0.069 g; 0.389 mmol) and 4-(3-aminopropyl)morpholine (170 μl; 1.17 mmol) in dichloromethane (6 ml) was stirred under argon atmosphere overnight. After removal of the insoluble material by filtration, the residue was purified on reverse phase silica eluting with a gradient of 40–50% methanol/ammonium carbonate buffer (2 g/l, pH7). The appropriate fractions were evaporated to dryness and triturated in ether to give (5S)-5-(acetylamino)-9,10,11-trimethoxy-N-(3-morpholinopropyl)-6,7-dihydro-5H-dibenzo[a,c]cycloheptene-3-carboxamide as a white solid.

1. customAfter removal of the insoluble material
2. filtrationby filtration
3. customthe residue was purified on reverse phase silica eluting with a gradient of 40–50% methanol/ammonium carbonate buffer (2 g/l, pH7)
4. customThe appropriate fractions were evaporated to dryness
5. customtriturated in ether